Host-directed immunotherapy of viral and bacterial infections: past, present and future
The advent of COVID-19 and the persistent threat of infectious diseases such as
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …
Alveolar macrophages in tissue homeostasis, inflammation, and infection: evolving concepts of therapeutic targeting
C Malainou, SM Abdin, N Lachmann… - The Journal of …, 2023 - Am Soc Clin Investig
Alveolar macrophages (AMs) are the sentinel cells of the alveolar space, maintaining
homeostasis, fending off pathogens, and controlling lung inflammation. During acute lung …
homeostasis, fending off pathogens, and controlling lung inflammation. During acute lung …
[HTML][HTML] COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly
variable disease severity and a bimodal course characterized by acute respiratory viral …
variable disease severity and a bimodal course characterized by acute respiratory viral …
Immunotherapy of COVID-19: inside and beyond IL-6 signalling
G Zizzo, A Tamburello, L Castelnovo, A Laria… - Frontiers in …, 2022 - frontiersin.org
Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open …
Background Dysregulated inflammation is associated with poor outcomes in COVID-19. We
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
C Bosteels, KFA Van Damme, E De Leeuw… - Cell Reports …, 2022 - cell.com
GM-CSF promotes myelopoiesis and inflammation, and GM-CSF blockade is being
evaluated as a treatment for COVID-19-associated hyperinflammation. Alveolar GM-CSF is …
evaluated as a treatment for COVID-19-associated hyperinflammation. Alveolar GM-CSF is …
Inflammatory pathways in COVID‐19: mechanism and therapeutic interventions
Y Jiang, T Zhao, X Zhou, Y Xiang… - MedComm, 2022 - Wiley Online Library
Abstract The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis.
In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive …
In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive …
Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury
GP Fadanni, JB Calixto - Cytokine & Growth Factor Reviews, 2023 - Elsevier
Acute respiratory distress syndrome (ARDS) is a heterogeneous cause of respiratory failure
that has a rapid onset, a high mortality rate, and for which there is no effective …
that has a rapid onset, a high mortality rate, and for which there is no effective …